Intra-Cellular Return on Investment Trend from 2010 to 2022

ITCI
 Stock
  

USD 59.99  1.22  2.08%   

Intra-Cellular Ther Return on Investment is increasing over the last several years with slightly volatile swings. Return on Investment is predicted to flatten to -57.36. During the period from 2010 to 2022 Intra-Cellular Ther Return on Investment regressed destribution of quarterly values had mean deviationof 18.54 and mean square error of  523.35. Intra-Cellular Ther Operating Expenses is most likely to increase significantly in the upcoming years. The last year's value of Operating Expenses was reported at 361.46 Million. The current Revenues is estimated to increase to about 90.4 M, while Consolidated Income is projected to decrease to (291.6 M).
  
Check Intra-Cellular Ther financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intra-Cellular main balance sheet or income statement drivers, such as Direct Expenses of 8.7 M, Cost of Revenue of 7.1 M or Gross Profit of 81.8 M, as well as many exotic indicators such as Calculated Tax Rate of 0.52, PPandE Turnover of 47.73 or Receivables Turnover of 6.23. Intra-Cellular financial statements analysis is a perfect complement when working with Intra-Cellular Ther Valuation or Volatility modules. It can also supplement Intra-Cellular Ther's financial leverage analysis and stock options assessment as well as various Intra-Cellular Ther Technical models . Please see the analysis of Intra-Cellular Ther Correlation against competitors.

Intra-Cellular Return on Investment Breakdown

Showing smoothed Return on Investment of Intra-Cellular Ther with missing and latest data points interpolated. Intra-Cellular Ther's Return on Investment historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intra-Cellular Ther's overall financial position and show how it may be relating to other accounts over time.
Return on Investment10 Years Trend
Increasing
Slightly volatile
   Return on Investment   
Share
       Timeline  

Intra-Cellular Return on Investment Regression Statistics

Arithmetic Mean(56.78)
Coefficient Of Variation(43.02)
Mean Deviation 18.54
Median(54.29)
Standard Deviation 24.43
Sample Variance 596.63
Range 69.78
R-Value 0.44
Mean Square Error 523.35
R-Squared 0.20
Significance 0.13
Slope 2.78
Total Sum of Squares 7,160

Intra-Cellular Return on Investment History

2013 -40.73
2015 -35.46
2016 -27.77
2017 -24.78
2018 -60.08
2020 -54.29
2021 -53.16
2022 -57.36

About Intra-Cellular Ther Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Intra-Cellular Ther income statement, its balance sheet, and the statement of cash flows. Intra-Cellular Ther investors use historical funamental indicators, such as Intra-Cellular Ther's Return on Investment, to determine how well the company is positioned to perform in the future. Although Intra-Cellular Ther investors may use each financial statement separately, they are all related. The changes in Intra-Cellular Ther's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intra-Cellular Ther's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Intra-Cellular Ther Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Intra-Cellular Ther. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Investment(53.16) (57.36) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Intra-Cellular Ther's public news can be used to forecast risks associated with investment in Intra-Cellular. The trend in average sentiment can be used to explain how an investor holding Intra-Cellular can time the market purely based on public headlines and social activities around Intra-Cellular Ther. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Intra-Cellular Ther's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intra-Cellular Ther's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intra-Cellular Ther's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Intra-Cellular Ther.

Intra-Cellular Ther Implied Volatility

    
  66.09  
Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Intra-Cellular Ther Correlation against competitors. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.5 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.